You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Poly-adenosine Ribose Phosphate Inhbitors (PARPi)

Showing 1 - 25 of 1,743
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Shanghai (Primary debulking surgery, Neoadjuvant

Not yet recruiting
  • Ovarian Cancer
  • +2 more
  • Primary debulking surgery
  • +2 more
  • Shanghai, China
    Zhongshan Hospital, Fudan University
Jan 17, 2022

Advanced Solid Tumors Trial in United States (KSQ-4279, KSQ-4279 will be combined in separate cohorts, including combination

Recruiting
  • Advanced Solid Tumors
  • KSQ-4279
  • KSQ-4279 will be combined in separate cohorts, including combination with an oral PARPi (poly adenosine diphosphate-ribose polymerase inhibitor)
  • Boston, Massachusetts
  • +4 more
Apr 5, 2022

Bespoke ctDNA Assay for Recurrence and Treatment Response

Recruiting
  • Ovarian Cancer
  • platinum-sensitive EOC
  • platinum-resistant and rEOC
  • Shanghai, Shanghai, China
    Hao Wen
Jul 5, 2022

Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jan 5, 2023

Breast Cancer Trial in Boston (Talazoparib, Sacituzumab Govitecan)

Recruiting
  • Breast Cancer
  • Boston, Massachusetts
  • +1 more
Jan 6, 2023

Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer Trial (Niraparib, Dostarlimab)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • +2 more
  • (no location specified)
Jul 26, 2022

Epithelial Ovarian Cancer Trial in Hangzhou (Pamiparib)

Not yet recruiting
  • Epithelial Ovarian Cancer
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Aug 4, 2022

Breast Cancer Trial in France (Main study:, Sub-study:)

Recruiting
  • Breast Cancer
  • Main study:
  • Sub-study:
  • Bordeaux, France
  • +20 more
Jan 2, 2023

Efficacy and Adverse Effects of Olaparib in Ovarian Cancer.

Enrolling by invitation
  • Ovarian Cancer
    • Xi'an, Shaanxi, China
      The First Affliated Hospital of Xi'an Jiaotong University
    Mar 23, 2022

    Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation Trial in San Francisco (Niraparib, Irinotecan)

    Not yet recruiting
    • Metastatic Solid Tumor
    • +4 more
    • San Francisco, California
      University of California, San Francisco
    Jan 12, 2023

    Tumors Trial in France, Spain, United Kingdom (Niraparib, Dostarlimab)

    Recruiting
    • Neoplasms
    • Brno, Czechia
    • +20 more
    Nov 21, 2022

    HRD Score in Chinese Ovarian Cancer Patients Benefiting From

    Recruiting
    • Ovarian Cancer
      • Shanghai, Shanghai, China
        The Obstetrics and Gynecology Hospital of Fudan University
      Feb 24, 2022

      Homologous Recombination Deficiency in Chinese Ovarian Cancer

      Not yet recruiting
      • Ovarian Cancer
      • +2 more
      • PARP inhibitor
      • Nanjing, Jiangsu, China
        Xiaoxiang Chen, MD,PhD
      Sep 4, 2021

      Variance of HRD From Paired Ovarian Cancer

      Not yet recruiting
      • Ovarian Cancer
      • +2 more
        • Nanjing, Jiangsu, China
          Xiaoxiang Chen
        Sep 25, 2021

        Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer Trial in United States (CB-839, Talazoparib)

        Terminated
        Has Results
        • Solid Tumor
        • +6 more
        • Birmingham, Alabama
        • +8 more
        Feb 16, 2022

        HRD and Resistance to PAPPi in EOC Patients

        Recruiting
        • Epithelial Ovarian Cancer
        • +6 more
        • Testing of homologous recombination deficiency
        • Beijing, Beijing, China
          Lei Li
        Mar 26, 2022

        Solid Tumors Trial in Worldwide (Tislelizumab, Pamiparib)

        Completed
        Has Results
        • Solid Tumors
        • Scottsdale, Arizona
        • +28 more
        Oct 27, 2021

        Advanced Solid Tumor, Metastatic Solid Tumor Trial (ART6043, Olaparib, Talazoparib)

        Not yet recruiting
        • Advanced Solid Tumor
        • Metastatic Solid Tumor
        • (no location specified)
        Jun 1, 2023

        Adrenal Gland Pheochromocytoma, Hematopoietic and Lymphoid System Tumor, Malignant Solid Tumor Trial run by the National Cancer

        Recruiting
        • Adrenal Gland Pheochromocytoma
        • +3 more
        • Computed Tomography
        • +2 more
        • Bethesda, Maryland
        • +1 more
        Jan 3, 2023

        Ovarian Cancer, Breast Cancer, Pancreatic Cancer Trial (HS-10502)

        Not yet recruiting
        • Ovarian Cancer
        • +4 more
        • (no location specified)
        Feb 24, 2023

        Collect Real-world Clinical and Patient-reported Outcomes in

        Recruiting
        • Ovarian Cancer
          • Aachen, Germany
          • +64 more
          Jul 29, 2022

          Ovarian Cancer Trial in Manchester (Olaparib, Cediranib, Platinum-based Chemotherapy)

          Completed
          • Ovarian Cancer
          • Manchester, United Kingdom
            The Christie NHS Foundation Trust
          Feb 4, 2022

          Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma Trial in Worldwide (Radiation Therapy, Temozolomide, Veliparib)

          Active, not recruiting
          • Anaplastic Astrocytoma
          • +2 more
          • Radiation Therapy
          • +2 more
          • Birmingham, Alabama
          • +162 more
          Dec 30, 2022

          Metastatic Cancer, Unspecified Adult Solid Tumor Trial in Los Angeles (PARP inhibitor BMN-673, temozolomide, irinotecan HCl)

          Completed
          • Metastatic Cancer
          • Unspecified Adult Solid Tumor
          • PARP inhibitor BMN-673
          • +4 more
          • Los Angeles, California
            Jonsson Comprehensive Cancer Center
          Sep 22, 2022

          Ovarian Cancer Trial in Toronto (Cediranib, Olaparib)

          Completed
          • Ovarian Cancer
          • Toronto, Ontario, Canada
            Princess Margaret Cancer Centre
          May 3, 2022